[¹⁸F]Fluorocholine and [¹⁸F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM.

ABSTRACT:

Purpose

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by inactivating mutations of the TSC1 or TSC2 gene, characterized by neurocognitive impairment and benign tumors of the brain, skin, heart, and kidneys. Lymphangioleiomyomatosis (LAM) is a diffuse proliferation of α-smooth muscle actin-positive cells associated with cystic destruction of the lung. LAM occurs almost exclusively in women, as a TSC manifestation or a sporadic disorder (TSC1/TSC2 somatic mutations). Biomarkers of whole-body tumor burden/activity and response to rapalogs or other therapies remain needed in TSC/LAM.

Experimental design

These preclinical studies aimed to assess feasibility of [¹⁸F]fluorocholine (FCH) and [¹⁸F]fluoroacetate (F

SUBMITTER: Verwer EE 

PROVIDER: S-EPMC6816044 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature